The information on this Website is not reliable and not intended to provide tax, legal, or investment advice. Nothing contained on the Website shall be considered a recommendation, solicitation, or offer to buy or sell a security to any person in any jurisdiction.
CEO.CA members discuss high-risk penny stocks which can lose their entire value. Only risk what you can afford to lose.
@anomalloy@Bullish you could be and should be right. $SXL bottomed out and undervalued imho, so you can't really get hurt at this point. Ditto for $AZX. Plus they just announced they expanded their U.S. market reach
@LGisntIT$FSW@jamjamhttps://m.youtube.com/watch?v=7ZFEMI9_Euo I got my wife to translate it - just basic stuff such as - now that they've won that award, it expands their capacity, opens up opportunities on working with others because everyone here is very friendly and open, and gives them the recognition to grab a bigger 'market' share. My wife isn't that into business, so not sure if she's translated well, which is why I put quotations around the word 'market'.
click to invite
anonymous$ICO March 11 Florida Presentation Bullous Pemphigoid showing pictures and working to remission in Article
EVENT March 11, 2017
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
results pending in Article Double-Blind, Placebo-ControlledOfficial Title:A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis